Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.59 |
| ▸ | BACE1 | P56817 | 10/20 | 0.58 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.58 |
| ▸ | CTSD | P07339 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.49 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30430659 | 0.91 | BACE1 (0.60) | TFPIBACE1BACE2CTSDOPRD1 | |
| SCHEMBL30865074 | 0.82 | NPY4R (0.60) | TFPIBACE1BACE2IL23R | |
| SCHEMBL30883259 | 0.82 | TFPI (0.62) | TFPIBACE1BACE2 | |
| SCHEMBL34460636 | 0.82 | CALCR (0.59) | TFPI | |
| SCHEMBL29356579 | 0.82 | GLP1R (0.56) | TFPIBACE1BACE2 | |
| SCHEMBL30512508 | 0.82 | OPRD1 (0.53) | BACE1BACE2CTSDOPRD1 | |
| SCHEMBL29649718 | 0.81 | OPRD1 (0.60) | BACE1BACE2CTSDOPRD1 | |
| SCHEMBL14005788 | 0.81 | BACE1 (0.59) | TFPIBACE1BACE2OPRD1CASP1 | |
| SCHEMBL30184264 | 0.81 | TFPI (0.62) | TFPIBACE1BACE2CTSD | |
| SCHEMBL30607373 | 0.80 | BACE1 (0.62) | BACE1BACE2CTSDOPRD1KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320250-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISCERAL PAIN | IRONWOOD PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| CN-118647392-A | Pharmaceutical composition for treating visceral pain | 硬木药品公司 | 2024-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320250-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISCERAL PAIN | VIP, FABP2, TRPV1 | TFPI 1899/4885BACE1 3210/4885BACE2 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.